Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy | Zendy

Lauren R. Cirrincione | Zendy; Anthony T. Podany | Zendy; Joshua P Havens | Zendy; Sara H Bares | Zendy; Shetty Ravi Dyavar | Zendy; Yeongjin Gwon | Zendy; Tanner M Johnson | Zendy; N. Jean Amoura | Zendy; Courtney V. Fletcher | Zendy; Kimberly K. Scarsi | Zendy

Open Access

Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy

Author(s) -

Lauren R. Cirrincione,

Anthony T. Podany,

Joshua P Havens,

Sara H Bares,

Shetty Ravi Dyavar,

Yeongjin Gwon,

Tanner M Johnson,

N. Jean Amoura,

Courtney V. Fletcher,

Kimberly K. Scarsi

Publication year - 2020

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkaa016

Subject(s) - tenofovir , emtricitabine , pharmacokinetics , medicine , pharmacology , transgender , sex hormone binding globulin , transgender women , human immunodeficiency virus (hiv) , antiretroviral therapy , hormone , virology , androgen , viral load , men who have sex with men , psychology , syphilis , psychoanalysis

Transwomen have an increased risk of HIV acquisition compared with other adults. Drug-drug interactions between pre-exposure prophylaxis (PrEP) and gender-affirming therapy are cited as a reason for poor PrEP uptake among transwomen. We evaluated plasma tenofovir and emtricitabine pharmacokinetics and their active intracellular anabolites, tenofovir-diphosphate and emtricitabine-triphosphate, in transwomen receiving feminizing hormones.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research